About BioIntelliSense
BioIntelliSense is a private company based in Golden, Colorado. It has reported $140,332,887 raised in four offerings on Form D since September 2020. Its chief executive is David Wang.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 4, 2025 | Dec 19, 2025amended Jun 4, 2026 | $58,349,365of $58.3M target | 14 | $4.1M | Equity, Offering of Preferred Stock and the underlying shares of Common Stock issuable upon conversion of Preferred Stock.Rule 506(b) | Form D/A ↗1 earlier filing |
| Apr 7, 2021 | Sep 15, 2022 | $44,985,854fully sold | 16 | $2.8M | Equity, Offering of Series B Preferred Stock ("Series B") and the underlying shares of Common Stock issuable upon conversion of Series B.Rule 506(b) | Form D ↗ |
| Aug 20, 2020 | Sep 10, 2020 | $12,000,003fully sold | 11 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Dec 14, 2018 | Sep 10, 2020 | $24,997,665of $25.0M target | 22 | $1.1M | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $140,332,887 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on BioIntelliSense's Form D filed Jun 4, 2026.
Earlier filings also listed Steve Hess (director, last listed Sep 2022), Larry Leisure (director, last listed Sep 2022), John Driscoll (director, last listed Sep 2022), Alan Meeker (director, last listed Sep 2022) and Ronald Chwang (director, last listed Sep 2020).